Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says
Maia Anderson | Becker’s Hospital Review
“An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.
The study — released Sept. 1 from the Washington, D.C.-based economic policy consulting firm and commissioned by the Coalition for Affordable Prescription Drugs — studied the effects of product hopping on the U.S. healthcare system.”
